Share

Save

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

PHASE1PHASE2RECRUITING

This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent).

info
Simpliy with AI

Study details:

This study consists of a Phase 1 portion and a Phase 2 portion. Phase 1 includes the following cohorts: Single dose-ascending cohorts and Multi- dose ascending cohorts of \[225Ac\]-FPI-1434 and Multi- dose ascending cohorts evaluating administration of FPI-1175 (cold antibody), followed by, \[225Ac\]-FPI-1434 (cold + hot), with cycles repeating every 42 days. And Cold Antibody Sub-study evaluating administration of ascending doses of FPI-1175 followed by \[111In\]-FPI-1547.

The Phase 2 will evaluate \[111In\]-FPI-1547 and \[225Ac\]-FPI-1434 with or without FPI-1175 in tumour-specific cohorts. The decision to utilize FPI-1175 in the Phase 2 portion of the study will be determined based on Phase 1 data, including safety, tolerability, pharmacokinetic and dosimetry results.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated, or the patient refuses standard therapy.
  • Measurable or evaluable disease in accordance with RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
  • Life expectancy of greater than 3 months as judged by the treating physician.
  • Available tumour tissue (either archival or fresh biopsy) for IGF-1R immunohistochemistry. Submission of the tissue is not required prior to enrollment.
  • Adequate heart, kidney, and liver function
  • Adequate bone marrow reserves
  • Ability to understand and the willingness to sign a written informed consent document.
  • Histologically and/or cytologically documented diagnosis of locally advanced, inoperable, metastatic, or recurrent solid tumour types: endometrial, cervical, ovarian, TNBC, HER 2-negative breast, HNSCC, ACC, or uveal melanoma.
  • Have measurable disease per RECIST 1.1 Failure to respond to standard systemic therapy, or for whom standard or curative systemic therapy does not exist or is not tolerable.
  • Prior to the initial [225Ac]-FPI-1434 cycle: Sufficient target expression in at least 1 lesion following [111In]-FPI-1547 and SPECT imaging.
  • Exclusion criteria

  • Systemic therapeutic radiopharmaceutical within 6 months prior to enrollment into this study.
  • Contraindications to or inability to perform the required imaging procedures in this study (e.g., inability to lay flat during scan time)
  • Uncontrolled brain metastasis, including but not limited to the need for treatment with steroids, surgery or radiation therapy.
  • Anticancer therapy (including investigational agents) or external beam radiation therapy within 14 days of the dosing of [111In]-FPI-1547
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years. Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast cancer, cervical cancer, prostate) that have undergone potentially curative therapy are not excluded.
  • Residual CTCAE ≥ Grade 2 side effects of prior therapy, with the exception of residual grade 2 alopecia.
  • Prior organ transplantation, including stem cell transplantation.
  • Any prior treatment with nitrosoureas or actinomycin-D.
  • Clinically relevant levels of protein in the urine
  • Known or suspected allergies or contraindications to the Investigational Products or any component of the investigational drug formulation.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Received > 20 Gy prior radiation to large areas of the bone marrow
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2019-01-17

    Primary completion: 2025-06-01

    Study completion finish: 2026-06-01

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE1

      PHASE2

    trial

    Trial ID

    NCT03746431

    Intervention or treatment

    DRUG: [111In]-FPI-1547 Injection

    DRUG: [225Ac]-FPI-1434 Injection multi-dose

    BIOLOGICAL: FPI-1175 Infusion

    DRUG: [225Ac]-FPI-1434 Injection single-dose

    Conditions

    • Ovarian Cancer
    • Advanced Solid Tumours
    • Endometrial Cancer
    • Cervical Cancer
    • Breast Cancer
    • Triple Negative Breast Cancer (TNBC)
    • HER2-negative Breast Cancer
    • Head and Neck Squamous Cell Carcinoma (HNSCC)
    • Adrenocortical Carcinoma
    • Uveal Melanoma
    Image related to Ovarian Cancer
    • Condition: Ovarian Cancer, Advanced Solid Tumours and more

    • DRUG: [111In]-FPI-1547 Injection and other drugs

    • Adelaide, South Australia, Australia and more

    • Sponsor: Fusion Pharmaceuticals Inc.

    Find a site

    Closest Location:

    Royal Adelaide Hospital

    Research sites nearby

    Select from list below to view details:

    • Royal Adelaide Hospital

      Adelaide, South Australia, Australia

    • Austin Hospital

      Heidelberg, Victoria, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: [225Ac]-FPI-1434 Single-Dose Escalation
    • Not Specified
    DRUG: [111In]-FPI-1547 Injection
    • \[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
    EXPERIMENTAL: [225Ac]-FPI-1434 Multi-Dose Escalation
    • \[225Ac\]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).
    DRUG: [111In]-FPI-1547 Injection
    • \[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
    EXPERIMENTAL: FPI-1175 Cold Antibody
    • Not Specified
    DRUG: [111In]-FPI-1547 Injection
    • \[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
    EXPERIMENTAL: [225Ac]-FPI-1434 Multi-Dose
    • Phase 2 Tumour Cohort - Head \& Neck Squamous Cell Carcinoma (HNSCC), Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative, Adrenocortical Carcinoma (ACC), Uveal Melanoma, \[225Ac\]-FPI-1434 treatment with or without pre-administration of FPI-1175 (cold antibody).
    DRUG: [111In]-FPI-1547 Injection
    • \[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Dose Escalation: Incidence of adverse events (AEs).Phase 1Approximately one year post final [225Ac]-FPI-1434 Injection.
    Single-Dose Escalation: Incidence of dose limiting toxicities (DLTs).Phase 18 weeks.
    Multi-Dose Escalation: Incidence of DLTs.Phase 16 weeks.
    Dose Escalation: Incidence of clinically significant clinical laboratory abnormalities.Phase 1Approximately one year post final [225Ac]-FPI-1434 Injection.
    Dose Escalation: Changes in electrocardiogram (ECG) parameters (PR, QRS, QT, and QTc intervals).Phase 14 weeks post final [225Ac]-FPI-1434 Injection.
    Cold Antibody Sub-Study: Changes in uptake of [111In]-FPI-1547 Injection following FPI-1175 Infusion in selected regions of interest on SPECT/CT images.Phase 1Within two weeks of the first [111In]-FPI-1547 Injection.
    Cold Antibody Sub-Study: Changes in radiation dose estimates for selected tissues, organs and whole body both for [111In]-FPI-1547 and [225Ac]-FPI-1434 Injection at various dose levels following FPI-1175 Infusion.Phase 1Within two weeks of the first [111In]-FPI-1547 Injection.
    Evaluate anti-tumour activity of [225Ac]-FPI-1434 regimenPhase 2Approximately one year post final [225Ac]-FPI-1434 injection.
    Objective response rate (ORR) RECIST v1.1.Phase 2Approximately one year post final [225Ac]-FPI-1434 Injection.

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Dose Escalation and Cold Antibody Sub-Study: Tumour uptake of [111In]-FPI-1547 in selected regions of interest on SPECT/CT images.Phase 1 and 2Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection.
    Dose Escalation: Radiation doses for selected organs and whole body both for [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.Phase 1 and 2Within one week of the [111In]-FPI-1547 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Changes in radiation absorbed doses for tumour lesions for [225Ac]-FPI-1434.Phase 1 and 2Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Clearance for radioactivity and for the targeting antibody.Phase 1 and 24 weeks post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Area under the curve (AUC) for radioactivity and for the targeting antibody.Phase 1 and 24 weeks post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Cmax for radioactivity and for the targeting antibody.Phase 1 and 24 weeks post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Half-life for radioactivity and for the targeting antibody.Phase 1 and 24 weeks post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Prostate Cancer Working Group 3 (PCWG3) guidelines.Phase 1Approximately one year post final [225Ac]-FPI-1434 Injection.
    Dose Escalation: Changes in the corrected QT (QTc) interval in milliseconds after [225Ac]-FPI-1434 treatment, compared to baseline.Phase 1 and 2Approximately 24 hours from the time of [225Ac]-FPI-1434 Injection administration.
    Dose Escalation and Cold-Antibody Sub-Study: Changes in human growth hormone (hGh) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.Phase 1 and 24 weeks post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor 1 (IGF-1) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.Phase 1 and 24 weeks post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor binding protein 3 (IGFBP-3) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.Phase 1 and 24 weeks post final [225Ac]-FPI-1434 Injection.
    Cold Antibody Sub-Study: Incidence of AEs.Phase 1 and 2Approximately one year post final [225Ac]-FPI-1434 Injection.
    Cold Antibody Sub-Study: Incidence of clinically significant clinical laboratory abnormalities.Phase 1 and 2Approximately one year post final [225Ac]-FPI-1434 Injection.
    Cold Antibody Sub-Study: Changes in ECG parameters (PR, QRS, QT, and QTc intervals).Phase 1 and 24 weeks post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Time to response (TTR).Phase 1 and 2Approximately one year post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Duration of response (DoR).Phase 1 and 2Approximately one year post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Progression free survival (PFS).Phase 1 and 2Approximately one year post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Time to Progression (TTP).Phase 1 and 2Approximately one year post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Disease control rate (DCR).Phase 1 and 2Approximately one year post final [225Ac]-FPI-1434 Injection.
    Dose Escalation and Cold-Antibody Sub-Study: Overall survival (OS).Phase 1 and 2Approximately one year post final [225Ac]-FPI-1434 Injection.

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

    Other trails to consider

    Top searched conditions